Effect of Terlipressin in the treatment of ascites-related acute kidney injury in liver cirrhosis
XU Aijing1* KONG Deliang2* LI Shuangxi2 YIN Wei1 HUANG Qianyun1 LI Chengzhong1
1.Department of Infectious Disease, the First Affiliated Hospital of Navy Military Medical University of Chinese People′s Liberation (Changhai Hospital), Shanghai 200433, China;
2.Department of Nephrology, the First Affiliated Hospital of Navy Military Medical University of Chinese People′s Liberation (Changhai Hospital), Shanghai 200433, China
Abstract：Objective To analyze the efficacy and recurrence rate of Terlipressin in the treatment of ascites-related acute renal injury (AKI) stage Ⅰ patients with cirrhosis. Methods Clinical data of 123 patients with AKI stage Ⅰ cirrhosis ascites treated in Changhai Hospital from January 2014 to February 2018 were collected and randomly divided into control group (n = 56) and observation group (n = 67) according to random number table method. Control group was given conventional treatment, and observation group was given Terlipressin on this basis. All patients were followed up for six months. Clinical efficacy of two groups was evaluated. The levels of total bilirubin (TBil), alanine aminotransferase (ALT), albumin, serum creatinine (Scr), serum sodium, international normalized ratio (INR), end-stage liver disease (MELD) score, MELD-Na score and estimated glomerular filtration rate (eGFR) were compared between two groups before treatment and after follow-up. The recurrence rate was compared between two groups. Results There were no significant differences in TBil, ALT, albumin, Scr, serum sodium, blood urea nitrogon (BUN), INR, MELD-Na score between two groups before treatment (P > 0.05). But eGFR of observation group was lower than that of control group before treatment (P < 0.05). TBil, ALT, Scr and INR of two groups after follow-up were lower than those before treatment, while albumin, MELD score, MELD-Na score and EGFR were higher than those before treatment (P < 0.05). TBil, Scr and BUN of observation group were lower than those of control group after follow-up, while albumin, MELD-Na score and eGFR of observation group were higher than those of control group (P < 0.05). The length of stay in observation group was significantly shorter than that in control group, and treatment response rate was significantly higher than that in control group (P < 0.05). There were no significant differences in recurrence rate and total recurrence rate between two groups after one, three and six months of follow-up (P > 0.05). Conclusion Terlipressin in the treatment of cirrhotic ascites AKI stage Ⅰ patients can effectively reduce Scr, BUN, albumin and eGFR, improve renal function, shorten the length of hospital stay, but has no significant effect on reducing the recurrence rate of AKI.
[1] Hamdy HS，El-Ray A，Salaheldin M，et al. Urinary neutrophil gelatinase-associated lipocalin in cirrhotic patients with acute kidney injury [J]. Ann Hepatol，2018，17（4）：624-630.
[2] Belcher JM，Sanyal AJ，Peixoto AJ，et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury [J]. Hepatology，2014，60（2）：622-632.
[3] Xiong J，Pu L，Xiong H，et al. Evaluation of the criteria of hepatorenal syndrome type of acute kidney injury in patients with cirrhosis admitted to ICU [J]. Scand J Gastroenterol，2018，53：1590-1596.
[4] Jaques DA，Spahr L，Berra G，et al. Biomarkers for acute kidney injury in decompensated cirrhosis：a prospective study [J]. Nephrology，2019，24（2）：170-180.
[5] Patil V，Jain M，Venkataraman J. Paracentesis-induced acute kidney injury in decompensated cirrhosis-prevalence and predictors [J]. Clin Exp Hepatol，2019，5（1）：55-59.
[6] Chancharoenthana W，Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease：where do we stand? [J]. World J Gastroenterol，2019，25（28）：3684-3703.
[7] Wong F. Treatment to improve acute kidney injury in cirrhosis [J]. Curr Treat Options Gastroenterol，2015，13（2）：235-248.
[8] 邢枫，李爽，张建军，等.特利加压素对顽固性肝硬化腹水的治疗作用与效应特点观察[J].中华肝脏病杂志，2019， 27（12）：982-988.
[9] Kam PC，Williams S，Yoong FF. Vasopressin and terlipressin：pharmacology and its clinical relevance [J]. Anaesthesia，2004，59（10）：993-1001.
[10] 程丹颖，万钢，欧蔚妮，等.特利加压素联合白蛋白治疗肝硬化急性肾损伤的临床疗效观察[J].中华肝脏病杂志，2019，27（9）：704-707.
[11] Angeli P，Ginès P，Wong F，et al. Diagnosis and management of acute kidney injury in patients with cirrhosis：revised consensus recommendations of the International Club of Ascites [J]. J Hepatol，2015，62（4）：968-974．
[12] Paolo A，Pere G，Florence W，et al. Diagnosis and management of acute kidney injury in patients with cirrhosis：revised consensus recommendations of the International Club of Ascitesq [J]. Gut，2015，64（4）：531-537.
[13] Bongers C，Alsady M，Nijenhuis T，et al. Impact of acute versus prolonged exercise and dehydration on kidney function and injury [J]. Physiol Rep，2018，6（11）：e13734.
[14] Lei L，Li L，Zhang H. Advances in the diagnosis and treatment of acute kidney injury in cirrhosis patients [J]. Biomed Res Int，2017，2017：8523649.
[15] Angeli P，Garcia-Tsao G，Nadim MK，et al. News in pathophysiology，definition and classification of hepatorenal syndrome：a step beyond the International Club of Ascites （ICA） consensus document [J]. J Hepatol，2019， 71（4）：811-822.
[16] Park SK，Ryoo JH，Oh CM，et al. The risk of type 2 diabetes mellitus according to 2-hour plasma glucose level：the Korean Genome and Epidemiology Study（KoGES） [J]. Diabetes Res Clin Pract，2018，146：130-137.
[17] Boyer TD，Sanyal AJ，Wong F，et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1 [J]. Gastroenterology，2016，150（7）：1579-1589.
[18] Demiselle J，Fage N，Radermacher P，et al. Vasopressin and its analogues in shock states：a review [J]. Ann Intensive Care，2020，10（1）：9.
[19] Wang H，Liu A，Bo W，et al. Terlipressin in the treatment of hepatorenal syndrome：a systematic review and meta-analysis [J]. Medicine（Baltimore），2018，97（16）：e0431.
[20] 熊号峰，刘景院.肝肾综合征研究进展[J].中国肝脏病杂志：电子版，2017，9（1）：1-6.
2020, Vol. 17 
京公网安备 11010502046598号